跳至主要内容
临床试验/NCT03193112
NCT03193112已完成不适用

Melatonin Decreases Eye Pressure in Depressive Patients With Normal Intraocular Pressure

Kahramanmaras Sutcu Imam University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2017年6月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
试验地点
1
主要终点
Intraocular pressure

研究概览

简要总结

Agomelatine is a melatonin drug used to treat depressive disorder. Agomelatine may also some effects on ocular pressures. In this study, we aimed to demonstrate that melatonin decreases intraocular pressures when given depressive patients.

详细描述

Melatonin has been shown to be effective to decrease intraocular pressure in experimental animal researches. Agomelatine is a melatonin derivative drug approved for the treatment of depression, which is also available in our country. Depending on animal experiments, it can be assumed that agomelatine can decrease intraocular pressure. Demonstrating that agomelatine is effective to reduce eye pressure may give a concurrent treatment of depressive patients with glaucoma. With this it may be possible to treat both diseases at the same time with single drug. In this study, the researchers intended to investigate the changes in ocular tension in normotensive depressive patients treated with agomelatine.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 66 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Depressive patients suitable for Agomelatine therapy for the treatment of their primary disease.

排除标准

  • Any past history of ocular surgery, ocular trauma or existing ocular diseases

研究组 & 干预措施

Study group

The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.

干预措施: Agomelatine 25 MG Oral Tablet (Drug)

结局指标

主要结局

Intraocular pressure

时间窗: One month

mmHg

次要结局

未报告次要终点

研究者

发起方
Kahramanmaras Sutcu Imam University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Gokhan Ozdemir

Principal investigator, Clinical Professor

Kahramanmaras Sutcu Imam University

研究点 (1)

Loading locations...

相似试验